WO2001002594A3 - DNA CONSTRUCTS BASED ON THE eIF4A GENE PROMOTER - Google Patents

DNA CONSTRUCTS BASED ON THE eIF4A GENE PROMOTER Download PDF

Info

Publication number
WO2001002594A3
WO2001002594A3 PCT/GB2000/002569 GB0002569W WO0102594A3 WO 2001002594 A3 WO2001002594 A3 WO 2001002594A3 GB 0002569 W GB0002569 W GB 0002569W WO 0102594 A3 WO0102594 A3 WO 0102594A3
Authority
WO
WIPO (PCT)
Prior art keywords
gene promoter
dna constructs
constructs
polynucleotide
eif4a
Prior art date
Application number
PCT/GB2000/002569
Other languages
French (fr)
Other versions
WO2001002594A2 (en
Inventor
David Robert Greaves
Lindy Thomsen
Ian Richard Catchpole
Martin James Ford
Original Assignee
Glaxo Group Ltd
David Robert Greaves
Lindy Thomsen
Ian Richard Catchpole
Martin James Ford
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9915638.2A external-priority patent/GB9915638D0/en
Priority claimed from GBGB9929547.9A external-priority patent/GB9929547D0/en
Application filed by Glaxo Group Ltd, David Robert Greaves, Lindy Thomsen, Ian Richard Catchpole, Martin James Ford filed Critical Glaxo Group Ltd
Priority to EP00942269A priority Critical patent/EP1190083A2/en
Priority to AU56971/00A priority patent/AU5697100A/en
Priority to JP2001508366A priority patent/JP2003504033A/en
Publication of WO2001002594A2 publication Critical patent/WO2001002594A2/en
Publication of WO2001002594A3 publication Critical patent/WO2001002594A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/46—Vector systems having a special element relevant for transcription elements influencing chromatin structure, e.g. scaffold/matrix attachment region, methylation free island
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The present invention provides novel DNA constructs comprising a transcriptional regulatory sequence comprising a polynucleotide derivable from the eIF4A1 gene promoter. In preferred embodiments, the polynucleotide further comprises a polynucleotide derivable from the eIF4A gene introns, particularly intron 1. Host cells harbouring the constructs are also provided. These novel constructs have applications in gene therapy, DNA vaccines and in the commercial production of proteins.
PCT/GB2000/002569 1999-07-06 2000-07-05 DNA CONSTRUCTS BASED ON THE eIF4A GENE PROMOTER WO2001002594A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP00942269A EP1190083A2 (en) 1999-07-06 2000-07-05 Dna constructs based on the eif4a gene promoter
AU56971/00A AU5697100A (en) 1999-07-06 2000-07-05 Dna constructs
JP2001508366A JP2003504033A (en) 1999-07-06 2000-07-05 DNA construct

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9915638.2 1999-07-06
GBGB9915638.2A GB9915638D0 (en) 1999-07-06 1999-07-06 DNA Constructs
GB9929547.9 1999-12-14
GBGB9929547.9A GB9929547D0 (en) 1999-12-14 1999-12-14 Dna constructs

Publications (2)

Publication Number Publication Date
WO2001002594A2 WO2001002594A2 (en) 2001-01-11
WO2001002594A3 true WO2001002594A3 (en) 2001-11-15

Family

ID=26315727

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2000/002569 WO2001002594A2 (en) 1999-07-06 2000-07-05 DNA CONSTRUCTS BASED ON THE eIF4A GENE PROMOTER

Country Status (4)

Country Link
EP (1) EP1190083A2 (en)
JP (1) JP2003504033A (en)
AU (1) AU5697100A (en)
WO (1) WO2001002594A2 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997042337A1 (en) * 1996-05-02 1997-11-13 Glaxo Group Limited Gene expression in monocytes and macrophages

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997042337A1 (en) * 1996-05-02 1997-11-13 Glaxo Group Limited Gene expression in monocytes and macrophages

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL SEQ. 6 August 1995 (1995-08-06), "EST; H. sapiens cDNA clone IMAGE:187152", XP002152483 *
DATABASE EMBL SEQUENCES 10 March 1998 (1998-03-10), "Mouse eIF4A gene", XP002152486 *
DATABASE EMBL SEQUENCES 14 December 1996 (1996-12-14), ANDERSSON B.: "Human clone 23933 mRNA", XP002152485 *
DATABASE EMBL SEQUENCES 15 February 2000 (2000-02-15), QUINN C.M.: "H. sapiens EIF4A1 gene", XP002152482 *
DATABASE EMBL SEQUENCES 7 October 1995 (1995-10-07), "EST; H. sapiens cDNA clone IMAGE:204614 similar ro eukaryotic initiation factor 4A-I.", XP002152484 *
JONES E. ET AL.: "The linked human elongation initiation factor 4A1 (eIF4A1) and CD68 genes map to chromosome 17p13", GENOMICS, vol. 53, 15 October 1998 (1998-10-15), pages 248 - 250, XP002157483 *
KUKIMOTO I. ET AL.: "Characterization of the cloned promoter of the human initiation factor 4AI gene", BIOCHEM. BIOPHYS. RES. COM., vol. 233, 1997, pages 844 - 847, XP002152479 *
MIYASHITA A. ET AL.: "Five different genes, Eif4a1, Cd68, Supl15h, Sox15 and Fxr2h, are clustered in a 40 kb region of mouse chromosome 11", GENE, vol. 237, no. 1, 3 September 1999 (1999-09-03), pages 53 - 60, XP004183497 *
QUINN C.M. ET AL.: "The human eukaryotic initiation factor 4AI gene (EIF4AI) contains multiple regulatory elements that direct high-level reporter gene expression in mammalian cell lines", GENOMICS, vol. 62, 15 December 1999 (1999-12-15), pages 468 - 476, XP002152480 *

Also Published As

Publication number Publication date
AU5697100A (en) 2001-01-22
EP1190083A2 (en) 2002-03-27
JP2003504033A (en) 2003-02-04
WO2001002594A2 (en) 2001-01-11

Similar Documents

Publication Publication Date Title
WO2000060058A3 (en) Polypeptides having alkaline alpha-amylase activity and nucleic acids encoding same
WO2000060060A3 (en) Polypeptides having alkaline alpha-amylase activity and nucleic acids encoding same
WO2001029222A3 (en) Polypeptides having phospholipase b activity and nucleic acids encoding same
WO2002046429A3 (en) Polypeptides having glucoamylase activity and nucleic acids encoding same
WO1998056927A3 (en) Nucleic acids encoding polypeptide having protease activity
IL127897A0 (en) Hamster ef-1alpha transcriptional regulatory dna
AU3246300A (en) Polypeptides having galactose oxidase activity and nucleic acids encoding same
WO2000061770A3 (en) Enhancement of the immune response for vaccine and gene therapy applications
WO2001079463A3 (en) Nucleic acids encoding polypeptides having haloperoxidase activity
WO2001079462A3 (en) Nucleic acids encoding polypeptides having haloperoxidase activity
CA2315274A1 (en) Polypeptides having aminopeptidase activity and nucleic acids encoding same
AU4777900A (en) Rnp originating in paramyxovirus
WO2002072845A3 (en) Salmonella promoter for heterologous gene expression
WO2003089598A3 (en) Polypeptides having xyloglucanase activity and nucleic acids encoding same
WO1997035005A3 (en) Cftr gene regulator
EP0804609A4 (en) NOVEL p53 RESPONSE GENES
EP0828003A3 (en) Human serine protease
AU5850999A (en) Fungal transcriptional activator useful in methods for producing polypeptides
AU7489098A (en) Polypeptides having aminopeptidase activity and nucleic acids encoding same
WO2001098469A3 (en) Polypeptides having peroxidase activity and nucleic acids encoding same
WO1995030757A3 (en) Metalloproteases from fusarium and aspergillus having thermolysin-like activity
WO2001002594A3 (en) DNA CONSTRUCTS BASED ON THE eIF4A GENE PROMOTER
EP1826272A3 (en) Flavobacterium genes
WO2000041509A3 (en) Polypeptides having acid phosphatase activity and nucleic acids encoding same
AU5727099A (en) A 2,6-beta-d-fructan hydrolase enzyme and processes for using the enzyme

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2000942269

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000942269

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)